Compare 10X Genomics Inc (TXG) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Workiva Inc — how do they compare? 10X Genomics Inc trades at $81.24 (market cap $10.07B), while Workiva Inc trades at $73.97 (market cap $4.01B). The key difference: 10X Genomics Inc is far larger — about 2.5× Workiva Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and Workiva Inc for 21 Days on average.
| TXG | WK | |
|---|---|---|
Market Cap | $10.07B | $4.01B |
Volume | 5,657,286 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $97.74 | $93.31 |
52-Week Low | $11.48 | $44.31 |
Typical Hold Time | 92 Days | 21 Days |
Enterprise Value | $9.59B | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
WK trades at $73.79, up 3.16% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $0.798. Revenue grew to $966 million in 2026, turning a net loss in 2025 into a $47 million profit. Analyst sentiment is overwhelmingly positive, with 16 buy ratings and a consensus price target of $86.
The outlook for WK is favorable, driven by consistent earnings outperformance and revenue growth, though high valuation multiples like a P/E of 87.73 pose risks. Key opportunities include AI-driven product innovations and inclusion in investment analyses, while risks involve competitive pressures and reliance on continued execution. The stock's proximity to its 52-week high suggests momentum but warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
